Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Auderghem – page 162

1 992 clinical trials in Auderghem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Auderghem at a glance
1 992
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 992 trials in Auderghem

Open in trial search

Study on Rifaximin for Delaying Hepatic Encephalopathy in Cirrhosis Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rifaximin
  • Sponsor:Salix Pharmaceuticals Inc.

Study on Ampreloxetine and Midodrine Hydrochloride for Treating Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ampreloxetine
  • Sponsor:Theravance Biopharma Ireland Limited

Marginal zone lymphoma+1

Not recruiting

Study Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:BeOne Medicines AG

Study on the Safety and Effects of BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BIIB080
  • Sponsor:Biogen Idec Research Limited

Crohn's disease

Not recruiting

Study on Ustekinumab for Children with Moderate to Severe Crohn's Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ustekinumab
  • Sponsor:Janssen Cilag International

Study on Valaciclovir to Prevent Congenital CMV Infection in Pregnant Women with First Trimester CMV Infections

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Valaciclovir
  • Sponsor:UZ Leuven

Hidradenitis

Not recruiting

Study on the Effects and Safety of SAR442970 for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:SAR442970
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Neurodermatitis

Not recruiting

Study on the Effectiveness and Safety of Ruxolitinib Cream for Patients with Prurigo Nodularis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Antipsychotics
  • Sponsor:Gilead Sciences Inc.

Study on Efinopegdutide and Semaglutide for Adults with Non-Alcoholic Steatohepatitis (NASH) Before Cirrhosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efinopegdutide
  • Sponsor:Merck Sharp & Dohme LLC

Study on ALLO-647 and ALLO-501A for Adults with Relapsed or Refractory Large B-Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ALLO-501A
  • Sponsor:Allogene Therapeutics Inc.

Febrile neutropenia

Not recruiting

Study on Shortening Antibiotic Treatment for Febrile Neutropenia in Hematology Patients Using Cefepime and Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cefepime
  • Sponsor:UZ Leuven

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Auderghem

What the registry says about research in the country

01 Neoplasms

In Auderghem, researchers are concentrating on lung cancer, specifically Non‑Small Cell Lung Cancer and small cell lung cancer. The two active studies compare new immune‑targeted agents such as pumitamig and obrixtamig against established therapies like pembrolizumab and standard chemotherapy, aiming to improve overall survival and disease control.

  • Comparative efficacy of novel immunotherapies
  • Evaluation of survival benefit in advanced disease
  • Biomarker‑guided patient selection (e.g., DLL3 expression)
  • Combination regimens with checkpoint inhibitors

Both trials are actively recruiting, reflecting a growing commitment in Auderghem to advance treatment options for patients with aggressive lung cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.